The Difference in Prognostic Factors between Early Recurrence and Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Nodal Stage Differently Impacts Early and Late Recurrence

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Ahn, Sung Gwe ^a   Lee, Hak Min ^a   Cho, Sang Hoon ^b   Bae, Suk Jin ^b   Lee, Seung Ah ^a   Hwang, Seung Hyun ^a   Jeong, Joon ^a   Lee, Hy De ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Soongsil University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

LETROZOLE; TAMOXIFEN; TOREMIFENE;

ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; COHORT ANALYSIS; DISTANT METASTASIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; PARTIAL MASTECTOMY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84878031369     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063510     Document Type: Article

References (27)

1. Parkin DM, Bray F, Ferlay J, Pisani P, (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
2. Karrison TG, Ferguson DJ, Meier P, (1999) Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst 91: 80-85.
3. Peto R, Boreham J, Clarke M, Davies C, Beral V, (2000) UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 355: 1822.
4. Saphner T, Tormey DC, Gray R, (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14: 2738-2746.
5. Dignam JJ, Dukic V, Anderson SJ, Mamounas EP, Wickerham DL, et al. (2009) Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer. Breast Cancer Res Treat 116: 595-602.
6. Hilsenbeck SG, Ravdin PM, de Moor CA, Chamness GC, Osborne CK, et al. (1998) Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 52: 227-237.
7. Early Breast Cancer Trialists' Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451-1467.
8. Cufer T, (2007) Reducing the risk of late recurrence in hormone-responsive breast cancer. Ann Oncol 18Suppl 8: viii18-25.
9. Kennecke HF, Olivotto IA, Speers C, Norris B, Chia SK, et al. (2007) Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Ann Oncol 18: 45-51.
10. Carter CL, Allen C, Henson DE, (1989) Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63: 181-187.
11. Demicheli R, Abbattista A, Miceli R, Valagussa P, Bonadonna G, (1996) Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res Treat 41: 177-185.
12. Kennecke H, McArthur H, Olivotto IA, Speers C, Bajdik C, et al. (2008) Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen. Cancer 112: 1437-1444.
13. Mansell J, Monypenny IJ, Skene AI, Abram P, Carpenter R, et al. (2009) Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer. Breast Cancer Res Treat 117: 91-98.
14. Bosco JL, Lash TL, Prout MN, Buist DS, Geiger AM, et al. (2009) Breast cancer recurrence in older women five to ten years after diagnosis. Cancer Epidemiol Biomarkers Prev 18: 2979-2983.
15. Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, et al. (2008) Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst 100: 1179-1183.
16. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, et al. (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134: e48-72.
17. Goss P, Allan AL, Rodenhiser DI, Foster PJ, Chambers AF, (2008) New clinical and experimental approaches for studying tumor dormancy: does tumor dormancy offer a therapeutic target? APMIS 116: 552-568.
18. Joensuu K, Hagstrom J, Leidenius M, Haglund C, Andersson LC, et al. (2011) Bmi-1, c-myc, and Snail expression in primary breast cancers and their metastases-elevated Bmi-1 expression in late breast cancer relapses. Virchows Arch 459: 31-39.
19. Joensuu K, Heikkila P, Andersson LC, (2008) Tumor dormancy: elevated expression of stanniocalcins in late relapsing breast cancer. Cancer Lett 265: 76-83.
20. Chen Q, Zhang XH, Massague J, (2011) Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell 20: 538-549.
21. Lu X, Mu E, Wei Y, Riethdorf S, Yang Q, et al. (2011) VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell 20: 701-714.
22. Oskarsson T, Acharyya S, Zhang XH, Vanharanta S, Tavazoie SF, et al. (2011) Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med 17: 867-874.
23. Bianchini G, Pusztai L, Iwamoto T, Kelly CM, Zambetti M, et al. (2011) Molecular tumor characteristics influence adjuvant endocrine treatment outcome. Cancer Research 71: Supplement 3.
24. Saghatchian M, Mittempergher L, Michiels S, Casinius S, Glas A, et al. (2011) Characterization of breast cancer distant metastasis based on outcome over time using a gene expression profiling approach and identification of pathway activities of late relapse. Cancer Research 71: Supplement 3.
25. Liu MC, Dixon JM, Xuan JJ, Riggins RB, Chen L, et al. (2011) Molecular signaling distinguishes early ER positive breast cancer recurrences despite adjuvant tamoxifen. Cancer Research 71: Supplement 3.
26. Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717.
27. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, et al. (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9: 45-53.